Longitudinal amyloid cognitive composite in preclinical Alzheimer's disease

Background and purpose Previous studies have developed several cognitive composites in preclinical Alzheimer disease (AD). However, more sensitive measures to track cognitive changes and therapeutic efficacy in preclinical AD are needed considering the diverse sociocultural and linguistic backgrounds. This study developed a composite score that can sensitively detect the amyloid-beta (A beta)-related cognitive trajectory of preclinical AD using Korean data. Methods A total of 196 cognitively normal participants who underwent amyloid positron emission tomography were followed-up with neuropsychological assessments. We developed the Longitudinal Amyloid Cognitive Composite in Preclinical AD (LACPA) using the linear mixed-effects model (LMM) and z scores. The LMM was also used to investigate the longitudinal sensitivity of the LACPA and the association between time-varying brain atrophy and the LACPA. Results Considering the group-time interaction effects of each subtest, the Seoul Verbal Learning Test-Elderly version immediate recall/delayed recall/recognition, the Korean Trail Making Test B Time, and the Korean Mini-Mental State Examination were selected as components of the LACPA. The LACPA exhibited a significant group-time interaction effect between the A beta+ and A beta- groups (t = -3.288, p = 0.001). Associations between time-varying LACPA and brain atrophy were found in the bilateral medial temporal, right lateral parietal, and right lateral frontal regions, and hippocampal volume. Conclusions The LACPA may contribute to reduction in time and financial burden when monitoring A beta-related cognitive decline and therapeutic efficacy of the disease-modifying agents specifically targeting A beta in secondary prevention trials.

Automated summary

This study developed a composite score that can sensitively detect the amyloid-beta (A beta)-related cognitive trajectory of preclinical AD using Korean data. The score may contribute to reduction in time and financial burden when monitoring A beta-related cognitive decline and therapeutic efficacy of the disease-modifying agents specifically targeting A beta in secondary prevention trials.